Autolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRA

The Medicines and Healthcare products Regulatory Agency of the U.K. reports that it granted a conditional marketing authorization for the medicine obecabtagene autoleucel, or Aucatzyl, a chimeric antigen receptor T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. The new conditional marketing authorization was granted on April 25 to Autolus Therapeutics (AUTL), the MHRA noted.